Johanna Diekmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johanna Diekmann has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Frank Michael Bengel
Hannover Medical School
6 shared publications Frank M. Bengel
Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany; and
4 shared publications- Thorsten Derlin
Hannover Medical School
4 shared publications James T. Thackeray
Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
3 shared publications- James T. Thackeray
Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
3 shared publications - Johann Bauersachs
Department of Cardiology and Angiology, Hannover Medical School , Hannover
3 shared publications
Latest Publications
- Top Cited Papers
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eadx1736
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
Vascular smooth muscle cell (VSMC) diversification drives atherosclerotic coronary artery disease (CAD), but the mechanisms governing these cell state transitions remain unclear. We applied multiomic single-cell profiling, epitope mapping, and spatial transcriptomics across 27 human coronary arteries, identifying fibroblast activation protein (FAP) as a marker of modulated VSMCs. Lineage tracing in mice indicated that FAP + cells originate from Myh11 + VSMCs, and FAP positron emission tomography imaging in CAD patients showed plaque uptake. FAP + cell states resided in the macrophage-rich neo-intima. Therapeutically, we developed an anti-FAP bispecific T cell engager, which reduced plaque burden and remodeled the stromal–immune microenvironment through T cell clonal expansion. Our study delivers a single-cell and spatial atlas of human CAD, establishes FAP as a marker of modulated VSMCs, and highlights immunotherapy for lipid-independent targets.
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eadx1736
Top Cited PapersTargeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
Vascular smooth muscle cell (VSMC) diversification drives atherosclerotic coronary artery disease (CAD), but the mechanisms governing these cell state transitions remain unclear. We applied multiomic single-cell profiling, epitope mapping, and spatial transcriptomics across 27 human coronary arteries, identifying fibroblast activation protein (FAP) as a marker of modulated VSMCs. Lineage tracing in mice indicated that FAP + cells originate from Myh11 + VSMCs, and FAP positron emission tomography imaging in CAD patients showed plaque uptake. FAP + cell states resided in the macrophage-rich neo-intima. Therapeutically, we developed an anti-FAP bispecific T cell engager, which reduced plaque burden and remodeled the stromal–immune microenvironment through T cell clonal expansion. Our study delivers a single-cell and spatial atlas of human CAD, establishes FAP as a marker of modulated VSMCs, and highlights immunotherapy for lipid-independent targets.
- Top Cited Papers
- 2 January 2026
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 23 (6) , 407-419
Molecular imaging of immune and fibrosis targets to guide therapy for repair after myocardial infarction
Heart injury after acute myocardial infarction requires adequate repair to prevent left ventricular remodelling and the development of chronic heart failure. The early immune response to myocardial injury and its tight interconnection to fibroblast activation have a crucial role in determining the outcome after myocardial infarction. Emerging therapies aim to exploit these targets, harnessing the subacute window after cardiac injury to prevent subsequent contractile dysfunction. Given the complexity of the tissue response to myocardial injury and the molecular specificity of targeted therapies, only a subgroup of individuals might benefit from these therapies, which emphasizes the need for personalized therapies and the identification of suitable biomarkers to classify patients. Radiotracer-based, non-invasive molecular imaging is rapidly evolving alongside targeted drug development, providing novel tools for the investigation of immune and profibrotic mechanisms. These molecular imaging techniques hold unique potential to guide the development and selection of reparative therapies based on precise information about the most suitable candidates and the timing after acute myocardial infarction. In this Review, we outline a roadmap for the clinical implementation of radiotracer-based molecular imaging of immune and fibrotic pathways to guide targeted therapies for heart repair. The long-term goal is to establish clinical algorithms for immune-targeted and fibrosis-targeted imaging-guided therapy for cardiac repair.
- 2 January 2026
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 23 (6) , 407-419
Top Cited PapersMolecular imaging of immune and fibrosis targets to guide therapy for repair after myocardial infarction
Heart injury after acute myocardial infarction requires adequate repair to prevent left ventricular remodelling and the development of chronic heart failure. The early immune response to myocardial injury and its tight interconnection to fibroblast activation have a crucial role in determining the outcome after myocardial infarction. Emerging therapies aim to exploit these targets, harnessing the subacute window after cardiac injury to prevent subsequent contractile dysfunction. Given the complexity of the tissue response to myocardial injury and the molecular specificity of targeted therapies, only a subgroup of individuals might benefit from these therapies, which emphasizes the need for personalized therapies and the identification of suitable biomarkers to classify patients. Radiotracer-based, non-invasive molecular imaging is rapidly evolving alongside targeted drug development, providing novel tools for the investigation of immune and profibrotic mechanisms. These molecular imaging techniques hold unique potential to guide the development and selection of reparative therapies based on precise information about the most suitable candidates and the timing after acute myocardial infarction. In this Review, we outline a roadmap for the clinical implementation of radiotracer-based molecular imaging of immune and fibrotic pathways to guide targeted therapies for heart repair. The long-term goal is to establish clinical algorithms for immune-targeted and fibrosis-targeted imaging-guided therapy for cardiac repair.
- 18 September 2025
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 66 (11) , 1750-1756
CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction
Acute myocardial infarction (AMI) triggers an inflammatory response, which is a determinant of subsequent healing. We speculated that C-X-C motif chemokine receptor 4 (CXCR4) upregulation early after AMI predicts left ventricular (LV) remodeling and cardiac structural functional outcome. Methods: In total, 49 patients underwent multimodal cardiac imaging including PET with the specific CXCR4 ligand 68Ga-pentixafor, myocardial perfusion imaging, and cardiac MR (CMR) within the first week after AMI. Follow-up CMR was acquired after 8.3 ± 4.2 mo in 40 patients. Results: Initial PET-derived CXCR4 expression in the infarct territory was significantly higher than blood pool (SUVpeak, 2.5 ± 0.5 vs. 2.0 ± 0.3; P < 0.001) but had high variance (1.5–4.2) among patients. The calculated area of CXCR4 upregulation (CXCR4 area, median 27.0% of LV; interquartile range [IQR], 11.0%–42.0%) was significantly larger than perfusion defect size (median 18% of LV; IQR, 3.0%–33.5%; P = 0.043) but not larger than the late gadolinium enhancement (LGE) extent in initial CMR (median 23.6% of LV; IQR, 18.2–30.3; P = 0.382). Myocardial CXCR4 area correlated with initial LV ejection fraction (LV-EF) (r = −0.533, P < 0.001), follow-up LV-EF (r = −0.420, P = 0.005), and initial LGE extent reflecting the area of myocardial injury (r = 0.559, P < 0.001). No correlation was found with LGE extent at follow-up. We investigated the association of baseline 68Ga-pentixafor uptake with functional outcome derived from follow-up CMR to established markers of myocardial damage. At 8-mo follow-up, a significant improvement in LV-EF (46.5 ± 10.3% vs. 49.1% ± 10.4%, P = 0.049) was noted, and the extent of LGE (% of LV) decreased (median 23.6% vs. 16.9% of LV; P < 0.001). The CXCR4 area emerged as an independent predictor of follow-up LV-EF (P = 0.049), outperforming baseline LGE extent (P = 0.318); however, its prognostic value diminished when accounting for initial perfusion defect, suggesting overlapping pathophysiologic information. Conclusion: CXCR4-targeted molecular imaging early after AMI bears potential to predict subsequent ventricular remodeling and may be a useful clinical tool for risk stratification and guidance of antiinflammatory therapies. Visual Abstract
- 18 September 2025
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 66 (11) , 1750-1756
CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction
Acute myocardial infarction (AMI) triggers an inflammatory response, which is a determinant of subsequent healing. We speculated that C-X-C motif chemokine receptor 4 (CXCR4) upregulation early after AMI predicts left ventricular (LV) remodeling and cardiac structural functional outcome. Methods: In total, 49 patients underwent multimodal cardiac imaging including PET with the specific CXCR4 ligand 68Ga-pentixafor, myocardial perfusion imaging, and cardiac MR (CMR) within the first week after AMI. Follow-up CMR was acquired after 8.3 ± 4.2 mo in 40 patients. Results: Initial PET-derived CXCR4 expression in the infarct territory was significantly higher than blood pool (SUVpeak, 2.5 ± 0.5 vs. 2.0 ± 0.3; P < 0.001) but had high variance (1.5–4.2) among patients. The calculated area of CXCR4 upregulation (CXCR4 area, median 27.0% of LV; interquartile range [IQR], 11.0%–42.0%) was significantly larger than perfusion defect size (median 18% of LV; IQR, 3.0%–33.5%; P = 0.043) but not larger than the late gadolinium enhancement (LGE) extent in initial CMR (median 23.6% of LV; IQR, 18.2–30.3; P = 0.382). Myocardial CXCR4 area correlated with initial LV ejection fraction (LV-EF) (r = −0.533, P < 0.001), follow-up LV-EF (r = −0.420, P = 0.005), and initial LGE extent reflecting the area of myocardial injury (r = 0.559, P < 0.001). No correlation was found with LGE extent at follow-up. We investigated the association of baseline 68Ga-pentixafor uptake with functional outcome derived from follow-up CMR to established markers of myocardial damage. At 8-mo follow-up, a significant improvement in LV-EF (46.5 ± 10.3% vs. 49.1% ± 10.4%, P = 0.049) was noted, and the extent of LGE (% of LV) decreased (median 23.6% vs. 16.9% of LV; P < 0.001). The CXCR4 area emerged as an independent predictor of follow-up LV-EF (P = 0.049), outperforming baseline LGE extent (P = 0.318); however, its prognostic value diminished when accounting for initial perfusion defect, suggesting overlapping pathophysiologic information. Conclusion: CXCR4-targeted molecular imaging early after AMI bears potential to predict subsequent ventricular remodeling and may be a useful clinical tool for risk stratification and guidance of antiinflammatory therapies. Visual Abstract
- Open Access
- 30 January 2025
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41 (3) , 537-548
Comparison of global and regional myocardial blood flow quantification using dynamic solid-state detector SPECT and Tc-99 m-sestamibi or Tc-99 m-tetrofosmin in a routine clinical setting
Solid-state detector single photon emission computed tomography (SPECT) enables the acquisition of dynamic data for calculation of myocardial blood flow (MBF) and myocardial flow reserve (MFR). Here, we report about our experiences on routine clinical use and robustness using Tc-99 m-sestamibi and Tc-99 m-tetrofosmin. 307 patients underwent dynamic list-mode myocardial perfusion imaging (MPI) and standard static MPI for clinical workup of coronary artery disease on a dedicated cardiac SPECT camera. After exclusion of 33 scans, 274 scans were eligible for MBF and MFR calculation using a 1‐tissue‐compartment model. Attenuation correction was performed for all patients using an external computed tomogram. Patients underwent stress-only scans, both stress and rest scans or rest-only scans using Tc-99 m-tetrofosmin or Tc-99 m-sestamibi. 30 patients without known cardiovascular comorbidities and without perfusion defect on static scans were compared in a sub analysis. Global stress myocardial blood flow (MBF) was significantly higher than rest MBF (2.3 vs. 1.1 ml/min/g; p < 0.001), and showed a high variability among individuals. Global myocardial flow reserve (MFR) was 2.1 (range 0.5–7.8). An analysis of 30 patients without known cardiovascular comorbidities yielded similar stress MBF measures for Tc-99 m-sestamibi and Tc-99 m-tetrofosmin (3.1 ± 1.2 vs. 2.8 ± 0.9 ml/min/g; p = 0.429). The use of attenuation correction lead to systematically lower MBF measures. Patients who underwent a one-day protocol had notably higher rest MBF (1.2 ± 0.5 vs. 1.0 ± 0.46 ml/min/g; p = 0.009) and consequently a lower MFR. Summed defect scores from standard static scans and presence of cardiovascular comorbidities negatively impacted MBF and MFR. Quantitative SPECT MBF and MFR in a clinical routine setting yields flow measures in range of expectation at an albeit wide range and is comprehensibly linked with results from standard static scan and patients history of cardiovascular diseases. Use of one-day protocols and attenuation correction systematically alters quantitative results. However, SPECT-derived MBF and MFR lack clinical reliability due to less validated reference ranges and high inter-individual variability. Graphical abstract
- 30 January 2025
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41 (3) , 537-548
Open AccessComparison of global and regional myocardial blood flow quantification using dynamic solid-state detector SPECT and Tc-99 m-sestamibi or Tc-99 m-tetrofosmin in a routine clinical setting
Solid-state detector single photon emission computed tomography (SPECT) enables the acquisition of dynamic data for calculation of myocardial blood flow (MBF) and myocardial flow reserve (MFR). Here, we report about our experiences on routine clinical use and robustness using Tc-99 m-sestamibi and Tc-99 m-tetrofosmin. 307 patients underwent dynamic list-mode myocardial perfusion imaging (MPI) and standard static MPI for clinical workup of coronary artery disease on a dedicated cardiac SPECT camera. After exclusion of 33 scans, 274 scans were eligible for MBF and MFR calculation using a 1‐tissue‐compartment model. Attenuation correction was performed for all patients using an external computed tomogram. Patients underwent stress-only scans, both stress and rest scans or rest-only scans using Tc-99 m-tetrofosmin or Tc-99 m-sestamibi. 30 patients without known cardiovascular comorbidities and without perfusion defect on static scans were compared in a sub analysis. Global stress myocardial blood flow (MBF) was significantly higher than rest MBF (2.3 vs. 1.1 ml/min/g; p < 0.001), and showed a high variability among individuals. Global myocardial flow reserve (MFR) was 2.1 (range 0.5–7.8). An analysis of 30 patients without known cardiovascular comorbidities yielded similar stress MBF measures for Tc-99 m-sestamibi and Tc-99 m-tetrofosmin (3.1 ± 1.2 vs. 2.8 ± 0.9 ml/min/g; p = 0.429). The use of attenuation correction lead to systematically lower MBF measures. Patients who underwent a one-day protocol had notably higher rest MBF (1.2 ± 0.5 vs. 1.0 ± 0.46 ml/min/g; p = 0.009) and consequently a lower MFR. Summed defect scores from standard static scans and presence of cardiovascular comorbidities negatively impacted MBF and MFR. Quantitative SPECT MBF and MFR in a clinical routine setting yields flow measures in range of expectation at an albeit wide range and is comprehensibly linked with results from standard static scan and patients history of cardiovascular diseases. Use of one-day protocols and attenuation correction systematically alters quantitative results. However, SPECT-derived MBF and MFR lack clinical reliability due to less validated reference ranges and high inter-individual variability. Graphical abstract
- 9 September 2024
- Published by Georg Thieme Verlag KG in Angewandte Nuklearmedizin
- Vol. 47 (03) , 166-174
Nuklearmedizinische Funktionsdiagnostik in der Kardiologie
Zusammenfassung: Herz-Kreislauf-Erkrankungen sind die häufigste Todesursache in Deutschland. In Kombination ermöglichen klinische Kriterien und geeignete Bildgebungsverfahren eine präzise Diagnosefindung und führen zur Einleitung einer passenden Therapie. Nuklearmedizinische bildgebende Verfahren sind Funktionsuntersuchungen, die biologische Prozesse sichtbar machen. Dieser Beitrag bietet eine Übersicht aktueller nuklearmedizinischer Bildgebungsmethoden für kardiale Fragestellungen.
- 9 September 2024
- Published by Georg Thieme Verlag KG in Angewandte Nuklearmedizin
- Vol. 47 (03) , 166-174
Nuklearmedizinische Funktionsdiagnostik in der Kardiologie
Zusammenfassung: Herz-Kreislauf-Erkrankungen sind die häufigste Todesursache in Deutschland. In Kombination ermöglichen klinische Kriterien und geeignete Bildgebungsverfahren eine präzise Diagnosefindung und führen zur Einleitung einer passenden Therapie. Nuklearmedizinische bildgebende Verfahren sind Funktionsuntersuchungen, die biologische Prozesse sichtbar machen. Dieser Beitrag bietet eine Übersicht aktueller nuklearmedizinischer Bildgebungsmethoden für kardiale Fragestellungen.
- 3 August 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 38, 102016
Strength in numbers: Advancing the clinical reality fibroblast activation protein imaging in cardiovascular disease
- 3 August 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 38, 102016
Strength in numbers: Advancing the clinical reality fibroblast activation protein imaging in cardiovascular disease
- 1 October 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (10) , e015009
Multicenter Evaluation of the Feasibility of Clinical Implementation of SPECT Myocardial Blood Flow Measurement: Intersite Variability and Imaging Time
Background: Single-center studies have shown that single photon emission computed tomography myocardial blood flow (MBF) measurement is accurate compared with MBF measured with microspheres in a porcine model, positron emission tomography, and angiography. Clinical implementation requires consistency across multiple sites. The study goal is to determine the intersite processing repeatability of single photon emission computed tomography MBF and the additional camera time required. Methods: Five sites (Canada, Italy, Japan, Germany, and Singapore) each acquired 25 to 35 MBF studies at rest and with pharmacological stress using technetium-99m-tetrofosmin on a pinhole-collimated cadmium-zinc-telluride–based cardiac single photon emission computed tomography camera with standardized list-mode imaging and processing protocols. Patients had intermediate to high pretest probability of coronary artery disease. MBF was measured locally and at a core laboratory using commercially available software. The time a room was occupied for an MBF study was compared with that for a standard rest/stress myocardial perfusion study. Results: With motion correction, the overall correlation in MBF between core laboratory and local site was 0.93 (range, 0.87–0.97) at rest, 0.90 (range, 0.84–0.96) at stress, and 0.84 (range, 0.70–0.92) for myocardial flow reserve. The local-to-core difference in global MBF (bias -MBF ) was 5.4% (−3.8% to 14.8%; median [interquartile range]) at rest and 5.4% (−6.2% to 19.4%) at stress. Between the 5 sites, bias -MBF ranged from −1.6% to 11.0% at rest and from −1.9% to 16.3% at stress; the interquartile range in bias -MBF was between 9.3% (4.8%–14.0%) and 22.3% (−10.3% to 12.0%) at rest and between 17.0% (−11.3% to 5.6%) and 33.3% (−10.4% to 22.9%) at stress and was not significantly different between most sites. Both bias and interquartile range were like previously reported interobserver variability and less than the SD of the test-retest difference of 30%. The overall difference in myocardial flow reserve was 1.52% (−10.6% to 11.3%). There were no significant differences between with and without motion correction. The average additional acquisition time varied between sites from 44 to 79 minutes. Conclusions: The average bias -MBF and bias -MFR values were small with standard deviations substantially less than the test-retest variability. This demonstrates that MBF can be measured consistently across multiple sites and further supports that this technique can be reliably implemented. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03427749.
- 1 October 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (10) , e015009
Multicenter Evaluation of the Feasibility of Clinical Implementation of SPECT Myocardial Blood Flow Measurement: Intersite Variability and Imaging Time
Background: Single-center studies have shown that single photon emission computed tomography myocardial blood flow (MBF) measurement is accurate compared with MBF measured with microspheres in a porcine model, positron emission tomography, and angiography. Clinical implementation requires consistency across multiple sites. The study goal is to determine the intersite processing repeatability of single photon emission computed tomography MBF and the additional camera time required. Methods: Five sites (Canada, Italy, Japan, Germany, and Singapore) each acquired 25 to 35 MBF studies at rest and with pharmacological stress using technetium-99m-tetrofosmin on a pinhole-collimated cadmium-zinc-telluride–based cardiac single photon emission computed tomography camera with standardized list-mode imaging and processing protocols. Patients had intermediate to high pretest probability of coronary artery disease. MBF was measured locally and at a core laboratory using commercially available software. The time a room was occupied for an MBF study was compared with that for a standard rest/stress myocardial perfusion study. Results: With motion correction, the overall correlation in MBF between core laboratory and local site was 0.93 (range, 0.87–0.97) at rest, 0.90 (range, 0.84–0.96) at stress, and 0.84 (range, 0.70–0.92) for myocardial flow reserve. The local-to-core difference in global MBF (bias -MBF ) was 5.4% (−3.8% to 14.8%; median [interquartile range]) at rest and 5.4% (−6.2% to 19.4%) at stress. Between the 5 sites, bias -MBF ranged from −1.6% to 11.0% at rest and from −1.9% to 16.3% at stress; the interquartile range in bias -MBF was between 9.3% (4.8%–14.0%) and 22.3% (−10.3% to 12.0%) at rest and between 17.0% (−11.3% to 5.6%) and 33.3% (−10.4% to 22.9%) at stress and was not significantly different between most sites. Both bias and interquartile range were like previously reported interobserver variability and less than the SD of the test-retest difference of 30%. The overall difference in myocardial flow reserve was 1.52% (−10.6% to 11.3%). There were no significant differences between with and without motion correction. The average additional acquisition time varied between sites from 44 to 79 minutes. Conclusions: The average bias -MBF and bias -MFR values were small with standard deviations substantially less than the test-retest variability. This demonstrates that MBF can be measured consistently across multiple sites and further supports that this technique can be reliably implemented. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03427749.
- 6 September 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 16 (10) , 1335-1347
Total-Body Positron Emission Tomography
- 6 September 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 16 (10) , 1335-1347
Total-Body Positron Emission Tomography
- 26 April 2023
- Published by Elsevier in PET Clinics
- Vol. 18 (3) , 389-396
Cardiac Applications of Fibroblast Activation Protein Imaging
- 26 April 2023
- Published by Elsevier in PET Clinics
- Vol. 18 (3) , 389-396
Cardiac Applications of Fibroblast Activation Protein Imaging
- 14 April 2022
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (02) , 137
Cardiac Fibroblast Activation in Patients After Acute Myocardial Infarction: Integration with Magnetic Resonance Tissue Characterization and Functional Outcome
Ziel/Aim After acute myocardial infarction (AMI), the area of fibroblast activation protein (FAP) upregulation exceeds the infarct region. We sought to obtain further insights by correlating FAP-targeted PET imaging with tissue characteristics from cardiac magnetic resonance (CMR) and functional outcome. Methodik/Methods 36 patients underwent CMR, perfusion SPECT, and 68Ga-FAPI-46 PET/CT within 11 days after AMI. Infarct size was determined from SPECT, compared to reference database. For PET, regional standardized uptake values (SUV) and isocontour volume-of-interests determined the extent of cardiac FAP upregulation (FAPI-volume). CMR yielded functional parameters, area of injury (late gadolinium enhancement, LGE) and T1/T2 tissue mapping. Follow up cardiac function was available from echocardiography or CMR after 214±133 days (n=14). Ergebnisse/Results The area of FAP-upregulation was significantly larger than SPECT perfusion defect size (58.3±15.3% vs. 23.5±17.3%, p<0.001) and infarct area by LGE (28.3±11.2%, p<0.001). FAPI-volume significantly correlated with CMR parameters at baseline (all p<0.001): infarct area (r=0.58), LV mass (r=0.69), endsystolic (r=0.62) and enddiastolic volume (r=0.57). Segmental analysis revealed FAP-upregulation in 328/512 (64%) myocardial segments. Significant LGE was found in only 56% of FAP-positive segments, elevated T1 in 41%, and elevated T2 in 68%. 21% of FAP-positive segments neither had prolonged T1 or T2 or significant LGE. Of note, LVEF at baseline correlated only weakly with FAPI-volume (r=0.32, p=0.07), while there was a significant correlation at follow-up (r=0.58, p=0.007). Schlussfolgerungen/Conclusions Early after acute myocardial infarction and reperfusion therapy, activation of fibroblasts markedly exceeds the hypoperfused infarct region and involves non-infarcted myocardium. The FAPI PET signal does not match regional myocardial tissue characteristics as defined by CMR, but it is predictive of the evolution of ventricular function. FAP-targeted imaging may provide a novel biomarker of left ventricular remodeling that is complementary to existing techniques. Publication Date: 14 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2022
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (02) , 137
Cardiac Fibroblast Activation in Patients After Acute Myocardial Infarction: Integration with Magnetic Resonance Tissue Characterization and Functional Outcome
Ziel/Aim After acute myocardial infarction (AMI), the area of fibroblast activation protein (FAP) upregulation exceeds the infarct region. We sought to obtain further insights by correlating FAP-targeted PET imaging with tissue characteristics from cardiac magnetic resonance (CMR) and functional outcome. Methodik/Methods 36 patients underwent CMR, perfusion SPECT, and 68Ga-FAPI-46 PET/CT within 11 days after AMI. Infarct size was determined from SPECT, compared to reference database. For PET, regional standardized uptake values (SUV) and isocontour volume-of-interests determined the extent of cardiac FAP upregulation (FAPI-volume). CMR yielded functional parameters, area of injury (late gadolinium enhancement, LGE) and T1/T2 tissue mapping. Follow up cardiac function was available from echocardiography or CMR after 214±133 days (n=14). Ergebnisse/Results The area of FAP-upregulation was significantly larger than SPECT perfusion defect size (58.3±15.3% vs. 23.5±17.3%, p<0.001) and infarct area by LGE (28.3±11.2%, p<0.001). FAPI-volume significantly correlated with CMR parameters at baseline (all p<0.001): infarct area (r=0.58), LV mass (r=0.69), endsystolic (r=0.62) and enddiastolic volume (r=0.57). Segmental analysis revealed FAP-upregulation in 328/512 (64%) myocardial segments. Significant LGE was found in only 56% of FAP-positive segments, elevated T1 in 41%, and elevated T2 in 68%. 21% of FAP-positive segments neither had prolonged T1 or T2 or significant LGE. Of note, LVEF at baseline correlated only weakly with FAPI-volume (r=0.32, p=0.07), while there was a significant correlation at follow-up (r=0.58, p=0.007). Schlussfolgerungen/Conclusions Early after acute myocardial infarction and reperfusion therapy, activation of fibroblasts markedly exceeds the hypoperfused infarct region and involves non-infarcted myocardium. The FAPI PET signal does not match regional myocardial tissue characteristics as defined by CMR, but it is predictive of the evolution of ventricular function. FAP-targeted imaging may provide a novel biomarker of left ventricular remodeling that is complementary to existing techniques. Publication Date: 14 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany